BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED Financials Biofil Chemicals and Pharmaceuticals Limited
Equities
BIOFILCHEM
INE829A01014
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.4 INR | +0.84% |
|
-0.60% | +24.67% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 244.1 | 107.6 | 120.4 | 1,068 | 940.6 | 674.4 |
| Enterprise Value (EV) 1 | 255.9 | 122.6 | 129.8 | 1,068 | 943.8 | 679.3 |
| P/E ratio | 51.9 x | 22.3 x | 10 x | 86.4 x | 135 x | 122 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.97 x | 0.47 x | 0.4 x | 2.95 x | 4.2 x | 2.25 x |
| EV / Revenue | 2.07 x | 0.53 x | 0.44 x | 2.95 x | 4.22 x | 2.26 x |
| EV / EBITDA | 25.5 x | 11.1 x | 6.58 x | 45 x | 64.6 x | 53.8 x |
| EV / FCF | -136 x | -27.9 x | 55.7 x | 1,760 x | -205 x | -587 x |
| FCF Yield | -0.73% | -3.58% | 1.8% | 0.06% | -0.49% | -0.17% |
| Price to Book | 1.85 x | 0.79 x | 0.81 x | 6.62 x | 5.59 x | 3.9 x |
| Nbr of stocks (in thousands) | 16,274 | 16,274 | 16,274 | 16,274 | 16,274 | 16,274 |
| Reference price 2 | 15.00 | 6.610 | 7.400 | 65.65 | 57.80 | 41.44 |
| Announcement Date | 8/13/18 | 8/30/19 | 9/5/20 | 9/1/21 | 9/5/22 | 9/2/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 123.6 | 231.3 | 298 | 361.8 | 223.8 | 300.4 |
| EBITDA 1 | 10.05 | 11.02 | 19.72 | 23.75 | 14.62 | 12.63 |
| EBIT 1 | 7.084 | 7.372 | 15.64 | 19.63 | 10.34 | 8.34 |
| Operating Margin | 5.73% | 3.19% | 5.25% | 5.43% | 4.62% | 2.78% |
| Earnings before Tax (EBT) 1 | 5.882 | 5.983 | 14.64 | 19.19 | 10.15 | 7.93 |
| Net income 1 | 4.707 | 4.823 | 12.07 | 12.41 | 6.984 | 5.604 |
| Net margin | 3.81% | 2.09% | 4.05% | 3.43% | 3.12% | 1.87% |
| EPS 2 | 0.2892 | 0.2964 | 0.7400 | 0.7600 | 0.4292 | 0.3400 |
| Free Cash Flow 1 | -1.878 | -4.388 | 2.332 | 0.6069 | -4.606 | -1.156 |
| FCF margin | -1.52% | -1.9% | 0.78% | 0.17% | -2.06% | -0.39% |
| FCF Conversion (EBITDA) | - | - | 11.82% | 2.56% | - | - |
| FCF Conversion (Net income) | - | - | 19.31% | 4.89% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/13/18 | 8/30/19 | 9/5/20 | 9/1/21 | 9/5/22 | 9/2/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 11.8 | 15 | 9.36 | - | 3.2 | 4.88 |
| Net Cash position 1 | - | - | - | 0.11 | - | - |
| Leverage (Debt/EBITDA) | 1.179 x | 1.362 x | 0.4746 x | - | 0.2188 x | 0.3861 x |
| Free Cash Flow 1 | -1.88 | -4.39 | 2.33 | 0.61 | -4.61 | -1.16 |
| ROE (net income / shareholders' equity) | 3.64% | 3.6% | 8.46% | 8.01% | 4.24% | 3.28% |
| ROA (Net income/ Total Assets) | 1.93% | 1.91% | 2.94% | 3.25% | 2.49% | 2.08% |
| Assets 1 | 244.5 | 253.2 | 411.1 | 382.5 | 280.7 | 269.5 |
| Book Value Per Share 2 | 8.090 | 8.390 | 9.150 | 9.910 | 10.30 | 10.60 |
| Cash Flow per Share 2 | 0.2300 | 0.0800 | 0.1600 | 0.2700 | 0.0900 | 0.0200 |
| Capex 1 | 3.79 | 14.1 | 2.07 | 5.67 | 0.7 | 0.11 |
| Capex / Sales | 3.06% | 6.11% | 0.69% | 1.57% | 0.31% | 0.04% |
| Announcement Date | 8/13/18 | 8/30/19 | 9/5/20 | 9/1/21 | 9/5/22 | 9/2/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +24.67% | 12.83M | |
| +21.72% | 43.81B | |
| +25.56% | 23.01B | |
| +19.03% | 15.27B | |
| +10.25% | 13.68B | |
| +43.25% | 11.96B | |
| -7.49% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.59B |
- Stock Market
- Equities
- BIOFILCHEM Stock
- Financials Biofil Chemicals and Pharmaceuticals Limited